CP6:F:F-The Cooper Companies Inc (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 80

Change

0.00 (0.00)%

Market Cap

USD 69.59B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

-1.05 (-0.29%)

USD 128.13B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

-1.00 (-0.97%)

USD 95.93B
ESL:F EssilorLuxottica Société ano..

+1.60 (+0.77%)

USD 92.21B
BOX:F Becton Dickinson and Company

-0.70 (-0.32%)

USD 64.97B
HYB:F HOYA Corporation

-2.30 (-2.00%)

USD 38.31B
HYB0:F HOYA CORP. ADR/ 1 O.N.

-3.00 (-2.63%)

USD 37.87B
RMEA:F Resmed Inc DRC

N/A

USD 29.63B
RME:F ResMed Inc

-3.20 (-1.58%)

USD 29.14B
CBHD:F Coloplast A/S

+1.20 (+1.07%)

USD 28.11B
CBH:F COLOPLAST SP.ADR 1/10 DK1

-0.10 (-0.90%)

USD 25.50B

ETFs Containing CP6:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.57% 46% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.57% 41% F 31% F
Trailing 12 Months  
Capital Gain -6.84% 59% D- 42% F
Dividend Return 0.01% 2% F N/A F
Total Return -6.83% 51% F 37% F
Trailing 5 Years  
Capital Gain 22.86% 62% D 59% D-
Dividend Return 0.05% 4% F N/A F
Total Return 22.91% 51% F 45% F
Average Annual (5 Year Horizon)  
Capital Gain 5.17% 72% C 65% D
Dividend Return 5.18% 65% D 59% D-
Total Return 0.01% 2% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 16.24% 64% D 67% D+
Risk Adjusted Return 31.91% 66% D+ 63% D
Market Capitalization 69.59B 97% N/A 97% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector